Efficacy of deferasirox through bioequivalence study in indonesian healthy volunteer

Asti Swari Paramanindita, Yahdiana Harahap, Tri Rahayu Wijayanti, Windy Lusthom, Budi Prasaja, Evan Widjaja, Monika Sandra, Girinanda Puspanegara

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: Deferasirox is an orally bioavailable synthetic, tridentate iron chelator that binds iron at a 2:1 ratio. The generic brand for this drug is still not available in Indonesia. We aimed to compare the efficacy between the generic drug and its innovator (Exjade®) by a study of bioequivalence in Indonesia among healthy volunteers. Methods: An open-label, single-dose, two-sequence, randomized two-way crossover study with one-week wash-out period was evaluated in 28 enrolled volunteers. Blood samples were collected up to 60 hours following drug administration. Deferasirox level was determined by HPLC method with ultraviolet detector. The pharmacokinetic parameters tested for bioequivalence assessment were AUC0-t, AUC0-∞, and Cmax. Results: The 90% confidence intervals obtained by analysis of variance for AUC0-t, AUC0-∞, and Cmax were 83.04%-95.53%, 83.18%-98.88%, and 81.67%-105.47%, respectively. These results were all within the range of 80.00-125.00%. Conclusion: Our results indicated that a single dose of 500 mg Deferasirox tablet demonstrated similar bioequivalence in terms of rate and extent of absorpstion to single dose of Exjade® 500 mg tablet.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalIranian Journal of Blood and Cancer
Issue number2
Publication statusPublished - Jun 2021


  • Bioequivalence
  • Deferasirox
  • Iron chelation
  • Pharmacokinetics
  • Thalassemia major


Dive into the research topics of 'Efficacy of deferasirox through bioequivalence study in indonesian healthy volunteer'. Together they form a unique fingerprint.

Cite this